This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 7, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Atossa Genetics, Inc. ("Atossa" or the "Company") (NasdaqCM: ATOS). Such investors are advised to contact
Peretz Bronstein or his investor Relation's coordinator
Eitan Kimelman at
email@example.com or 212-697-6484.
The investigation concerns whether Atossa and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On
October 7, 2013, shares of Atossa fell
$2.48 or 46.62% in premarket trading after the company issued a press release on
October 4, 2013, after the close of trading, announcing it had commenced the voluntary recall of the ForeCYTE Breast Health Test Mammary Aspiration Specimen Cytology Test (MASCT). In
February 2013, the Company received a warning letter from U.S. Food and Drug Administration ("FDA"). The FDA raised concerns about (1) the current instructions for use (IFU); (2) certain promotional claims used to market these devices; and (3) the need for FDA clearance for certain changes made to the Nipple Aspirate Fluid (NAF) specimen collection process identified in the current IFU. Atossa will remove existing product from the market until FDA's concerns are addressed.
If you are aware of any facts relating to this investigation, or purchased shares of Atossa, you can assist this investigation by contacting
Peretz Bronstein or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.